{"id":"https://openalex.org/W3031042153","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","title":"Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).","display_name":"Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients with AML who are unfit for intensive chemotherapy (IC).","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3031042153","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","mag":"3031042153"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.tps7567","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035236340","display_name":"Tara L. Lin","orcid":"https://orcid.org/0000-0002-0242-6449","observed_orcids":["https://orcid.org/0000-0002-0242-6449"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tara L. Lin","raw_affiliation_strings":["University of Kansas Medical Center, Kansas City, KS;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kansas Medical Center, Kansas City, KS;","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101423957","display_name":"Geoffrey L. Uy","orcid":"https://orcid.org/0000-0002-7809-0996","observed_orcids":["https://orcid.org/0000-0002-7809-0996"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey L. Uy","raw_affiliation_strings":["Washington University School of Medicine, St. Louis, MO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, St. Louis, MO;","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013626352","display_name":"Roland B. Walter","orcid":"https://orcid.org/0000-0002-9268-3341","observed_orcids":["https://orcid.org/0000-0002-9268-3341"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland B. Walter","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000228105","display_name":"Heng Zou","orcid":"https://orcid.org/0000-0002-3683-7916","observed_orcids":["https://orcid.org/0000-0002-3683-7916"]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heng Zou","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA;","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Qi Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qi Wang","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA;","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026347795","display_name":"Stefan Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Faderl","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA;","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015425440","display_name":"Ronald S. Cheung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Cheung","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA;","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024492683","display_name":"Vinod A. Pullarkat","orcid":"https://orcid.org/0000-0001-9129-3424","observed_orcids":["https://orcid.org/0000-0001-9129-3424"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vinod A. Pullarkat","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center, Duarte, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Duarte, CA;","institution_ids":["https://openalex.org/I1301076528"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"TPS7567","last_page":"TPS7567"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.8889999985694885},{"id":"https://openalex.org/keywords/cpx-351","display_name":"CPX-351","score":0.9769999980926514},{"id":"https://openalex.org/keywords/vyxeos","display_name":"Vyxeos","score":0.8989999890327454},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9900000095367432},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7229999899864197},{"id":"https://openalex.org/keywords/unfit-patients","display_name":"unfit patients","score":0.5329999923706055},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7860000133514404},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8100000023841858},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8899999856948853},{"id":"https://openalex.org/keywords/low-dose-cytarabine","display_name":"low-dose cytarabine","score":0.8410000205039978},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5400000214576721},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.6830000281333923},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7400000095367432}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.9471967220306396},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8238813281059265},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7434805631637573},{"id":"https://openalex.org/C2781021840","wikidata":"https://www.wikidata.org/wiki/Q411659","display_name":"Daunorubicin","level":3,"score":0.5346853733062744},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5053094029426575},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45675477385520935},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4499005079269409},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3339705765247345},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.32678085565567017},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.tps7567","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.tps7567","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7799999713897705,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320312570","display_name":"Jazz Pharmaceuticals","ror":"https://ror.org/055mhsv54"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2147459960","https://openalex.org/W2801436543","https://openalex.org/W1964648983","https://openalex.org/W3046856303","https://openalex.org/W4210811689","https://openalex.org/W4313390310","https://openalex.org/W2187158199","https://openalex.org/W2077348867","https://openalex.org/W1818146702","https://openalex.org/W2071961017"],"abstract_inverted_index":{"TPS7567":[0],"Background:":[1],"CPX-351":[2,53,75,111,118,156,180,238],"(Vyxeos;":[3],"daunorubicin":[4],"and":[5,15,61,103,112,148,153,186,192,263,268,280,294],"cytarabine":[6,96],"liposome":[7],"for":[8,17,51,83,101,109,128,259,271],"injection)":[9],"is":[10,132,292],"approved":[11],"by":[12,213,261],"the":[13,18,77,143,150,166,169,206,242,253],"FDA":[14],"EMA":[16],"treatment":[19],"of":[20,155,201,237,278,288],"adults":[21],"with":[22,29,43,94,122,208],"newly":[23,44],"diagnosed":[24,45],"therapy-related":[25],"AML":[26,28,47,98,125],"or":[27,222,227],"myelodysplasia-related":[30],"changes.":[31],"In":[32,168,241],"a":[33,63,86,107,214],"phase":[34,137,171],"3":[35,193],"study":[36,115,139,291],"in":[37,80,92,97,120,124,165],"patients":[38],"(pts)":[39],"aged":[40],"60-75":[41],"y":[42],"high-risk/secondary":[46],"who":[48,219],"were":[49],"fit":[50],"IC,":[52,102],"significantly":[54],"improved":[55],"median":[56],"survival":[57,281],"versus":[58],"7+3":[59],"cytarabine/daunorubicin":[60],"had":[62],"comparable":[64],"safety":[65,215,272],"profile.":[66],"However,":[67],"it":[68],"may":[69,230],"not":[70],"be":[71,250],"appropriate":[72],"to":[73,141,175,204,233,283],"administer":[74],"at":[76,252],"label":[78],"dosage":[79],"pts":[81,99,126,177,248,256],"unfit":[82,100,127],"IC.":[84,129],"Venetoclax,":[85],"BCL-2":[87],"inhibitor,":[88],"has":[89],"clinical":[90],"efficacy":[91],"combination":[93,121],"low-dose":[95],"preclinical":[104],"data":[105],"suggest":[106],"rationale":[108],"combining":[110],"venetoclax.":[113,159,240],"This":[114,131],"thus":[116],"evaluates":[117],"LIT":[119,157],"venetoclax":[123,195],"Methods:":[130],"an":[133,245],"open-label,":[134],"multicenter,":[135],"2-part,":[136],"1b":[138],"(NCT04038437)":[140],"determine":[142,205],"maximum":[144],"tolerated":[145],"dose":[146,210],"(MTD)":[147],"evaluate":[149],"safety,":[151],"efficacy,":[152],"pharmacokinetics":[154],"plus":[158,194,239],"Key":[160],"eligibility":[161],"criteria":[162],"are":[163,257,269],"shown":[164],"Table.":[167],"dose-escalation":[170],"(3+3":[172],"design),":[173],"up":[174,232],"24":[176],"will":[178,249],"receive":[179,231],"(dose":[181],"levels:":[182],"20,":[183],"40,":[184],"60,":[185],"75":[187],"units/m2)":[188],"on":[189,198],"Days":[190,199],"1":[191,226,274,284],"400":[196],"mg":[197],"2-21":[200],"each":[202,209],"cycle":[203],"MTD,":[207],"escalation":[211],"confirmed":[212],"assessment":[216],"committee.":[217],"Pts":[218],"achieve":[220],"complete":[221],"partial":[223],"remission":[224],"after":[225,276,286],"2":[228],"cycles":[229,236],"4":[234],"similar":[235],"expansion":[243],"phase,":[244],"additional":[246],"20":[247],"treated":[251],"MTD.":[254],"All":[255],"assessed":[258],"response":[260],"morphology":[262],"minimal":[264],"residual":[265],"disease":[266],"testing,":[267],"monitored":[270],"(until":[273],"month":[275],"end":[277],"treatment)":[279],"(up":[282],"year":[285],"start":[287],"treatment).":[289],"The":[290],"ongoing":[293],"actively":[295],"enrolling":[296],"pts.":[297],"Clinical":[298],"trial":[299],"information:":[300],"NCT04038437":[301],".":[302],"[Table:":[303],"see":[304],"text]":[305]},"counts_by_year":[{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}